ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1485	National Cancer Institute	Html	en	Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of intraocular (eye) melanoma.	uveal melanoma 0.68476 Medium Tumor Trial 0.539127 charged-particle ebrt 0.585479 local tumor regrowth 0.547533 125I brachytherapy 0.543775 uveal melanomas 0.962507 Option Overview section 0.565872 local tumor recurrence. 0.544248 posterior uveal melanomas 0.679007 plaque radiation therapy 0.595583 tumor regression rates 0.537853 uveal tract melanomas 0.717461 late local radiation 0.532096 ocular melanoma 0.519667 histopathologically confirmed melanoma 0.546989 large choroidal tumors 0.551303 small melanomas 0.610711 brachytherapy 0.555626 all-cause mortality rates 0.515468 U.S. incidence rates 0.52364 local control rate 0.579941 melanoma metastasis-specific survival 0.54531 prominent tumor vascularity 0.525035 posterior melanomas 0.676788	large uveal melanomas 0.659428 patients 0.552792 visual acuity 0.646161 optic disc 0.638287 ciliary body 0.761795 small choroidal melanoma 0.601669 ciliary body melanoma 0.589002 medium-sized choroidal tumors 0.551291 relatively good outcomes 0.576295 tumors 0.574964 Treatment Option Overview 0.566892 tumor growth warrants 0.54471 posterior uveal tract 0.542964 tumor 0.654818 unequivocal tumor growth 0.619495 anterior ciliary body 0.517737 radiation therapy 0.658453 local tumor control 0.613746 ocular melanomas 0.634519 typical choroidal melanoma 0.592701 statistically significant differences 0.571591 small choroidal melanomas 0.778268 iris melanomas 0.919191	CLICK HERE
1551	National Cancer Institute	Html	null	Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders.			CLICK HERE
1656	National Cancer Institute	Html	null	Last Days of Life (PDQ®)–Health Professional Version	Expert-reviewed information summary about care during the last days to last hours of life, including common symptoms, ethical dilemmas that may arise, and the role of the oncologist in caring for patients and their families during this time.			CLICK HERE
1842	National Cancer Institute	Html	es	Tratamiento del cáncer de endometrio (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de endometrio.	Endometrial Cancer Group 0.318951 Obstet Gynecol 0.338539 papillary serous carcinoma 0.328892 uterine papillary serous 0.337487 positive peritoneal cytology 0.310059 with low-risk stage 0.308461 endometrial carcinoma 0.512882 prognostic factors 0.307871 Radiat Oncol Biol 0.365388 surgical staging 0.309654 laparoscopy versus laparotomy 0.308759 oncology group study 0.336362 endometrio estadio 0.314607 prognostic significance 0.310042 Natl Cancer Inst 0.338736 Gynecologic Oncology Group 0.394499 cancer staging 0.313796 Gynecol Oncol 0.593302 patients with 0.367043 radiation therapy 0.313526 Braquiterapia vaginal posoperatoria 0.30677 endometrial cancer 0.978339 peritoneal cytology 0.312286 stage-1 endometrial carcinoma 0.31493 cases with carcinoma 0.307561	Operative Radiation Therapy 0.306859 Lancet Oncol 0.306692 with endometrial carcinoma 0.344016 Danish Endometrial Cancer 0.332392 estadio iv 0.31911 estadio ii 0.371493 with surgical stage 0.316597 Cancer Staging Manual 0.308545 Féderation Internationale 0.308609 endometrial carcinoma only 0.316396 Endometrial Cancer Study 0.319041 stage i-ii papillary 0.306581 endometrial carcinoma among 0.316625 Clin Oncol 0.320098 surgical stage 0.327711 Oncol Biol Phys 0.368458 Cancer Genome Atlas 0.314564 estadio iii 0.309959 clinical stage 0.315784 cuello uterino 0.329408 Gynecol Cancer 0.309855 vaginal brachytherapy 0.308102 treated with 0.309769 with or without 0.308543	CLICK HERE
2003	National Cancer Institute	Html	es	Tratamiento de los tumores de estroma gastrointestinal (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de estroma gastrointestinal	Corless CL 0.538141 Gastric stromal sarcoma 0.50605 stromal tumors irrespective 0.50378 Gastrointestinal pacemaker 0.510002 cases with 0.505031 Demetri GD 0.510561 antígeno cd117 0.5043 stromal tumors but 0.503793 Sin embargo 0.508884 KIT-negative gastrointestinal 0.505275 gastrointestinal stromal sarcomas 0.507782 gen kit 0.50569 Cancer Res 0.504191 sclerosing stromal tumors 0.504057 receptor kit 0.508691 with mutational analysis 0.504267 stromal tumor patient 0.504863 Multiple gastrointestinal 0.505317 before imatinib with 0.505687 PDGFRA activating mutations 0.504562 Oncol Rep 0.503948 nervioso autónomo gastrointestinal 0.506079 interstitial cells 0.505694 TEGI primario recién 0.504948 new cases with 0.504631	verdadero tegi 0.504221 stromal tumor occurs 0.504698 gastric stromal tumours 0.506473 microscopic gastrointestinal 0.505987 gastrointestinal tract 0.505493 gastrointestinal stromal tumors 0.979159 Surg Pathol 0.538619 Duensing A 0.505663 tumors have unique 0.505149 molecular genetic study 0.50922 Cancer Staging Manual 0.525628 tirosina cinasa kit 0.507752 tirosina cinasa 0.607449 proteína cinasa 0.508725 Heinrich MC 0.512562 carney triad 0.506455 gastrointestinal stromal tumours 0.529292 with long-term follow-up 0.503857 stromal sarcoma 0.507115 metastatic gastrointestinal 0.505468 NF1-associated gastrointestinal 0.509992 ANNUAL REVIEWS 0.505692 pacemaker cell tumor 0.506911 AJCC Cancer Staging 0.518324	CLICK HERE
2014	National Cancer Institute	Html	es	Aspectos generales de los exámenes de detección del cáncer (PDQ®)–Versión para profesionales de salud	Información sobre la medición de la eficacia de las pruebas de detección del cáncer y la evaluación de la solidez de las pruebas obtenidas en estudios de investigación de detección del cáncer.	Does screening 0.616458 importancia clínica 0.620073 muertes prematuras 0.612815 American Cancer Society 0.649437 Woods WG 0.609081 shared decision-making 0.610684 únicos exámenes 0.617228 Malmo mammographic screening 0.618339 case-control studies 0.618658 Instituto Nacional 0.618095 SEER Program 0.61206 examen tisular 0.612004 patient decision aids 0.642735 Estados Unidos 0.671925 Clin Epidemiol 0.61257 Natl Cancer Inst 0.655145 screening with 0.61747 screening efficacy 0.629033 cancer screening 0.803421 Kramer BS 0.609339 estadio iv 0.624173 Cancer Intervention 0.613844 End Results 0.611945 Evaluating new screening 0.618163 voluntarios sanos 0.610696	Decision Aid Standards 0.609164 sobrediagnóstico resultante 0.608646 diagnosed with 0.611303 decision aid 0.652528 Cancer Facts 0.614043 Day NE 0.608989 datos probatorios indirectos 0.611287 evaluating neuroblastoma screening 0.619704 Welch HG 0.609007 mammography screening 0.616883 cancer screening strategies 0.649219 Intern Med 0.611038 breast cancer screening 0.675789 Clin Oncol 0.611547 Cancer screening among 0.630365 systematic review 0.61189 cáncer surveillance 0.636085 Mass screening 0.616536 cuello uterino 0.611009 Neuroblastoma Screening Project 0.622021 datos probatorios 0.981275 Black WC 0.609219 mejores desenlaces 0.609922 Cancer Screening Trial 0.636288	CLICK HERE
2032	National Cancer Institute	Html	es	Exámenes de detección del cáncer de próstata (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar el cáncer de próstata.	or watchful waiting 0.527761 Prostate Cancer Group-4 0.536467 Koyama T 0.514342 estudio erspc 0.525762 Sin embargo 0.633101 Resnick MJ 0.514745 países cuáles factores 0.523397 detección versus 0.572904 Holmberg L 0.514356 ensayo plco 0.516954 Swedish Cancer Registry 0.524495 Ahmed HU 0.514521 jurisdicciones europeas colaboradoras 0.519184 Preventive Services Task 0.58607 Ovarian Cancer Screening 0.580102 consiguiente tratamiento 0.524752 Croswell JM 0.515275 estudio prostate testing 0.532458 Estados Unidos 0.630717 centro göteborg 0.570246 siguientes tasas 0.517703 Prostate Cancer Prevention 0.525333 PSA rutinarias 0.626469 FJ Jr 0.514192 evolución natural benigna 0.523168	centro sueco göteborg 0.523946 trascendencia clínica 0.542862 Lancet Oncol 0.516366 Eur Urol 0.51628 End Results 0.514418 Loeb S 0.514034 Scandinavian Prostate Cancer 0.583772 seguimiento diagnóstico 0.518794 Gen Intern Med 0.526679 lesiones prostáticas benignas 0.525347 radical prostatectomy 0.520653 Países Bajos 0.556513 Fan KH 0.51463 edad promedio 0.515679 Chou R 0.514768 PDQ Tratamiento 0.51809 European Randomized Study 0.573324 Intern Med 0.549412 Steineck G 0.514536 Services Task Force 0.584434 prostate cancer 0.738954 datos probatorios 0.915311 Prostate Intervention Versus 0.524636 Cancer Screening Trial 0.580497	CLICK HERE
15637	National Cancer Institute	Html	null	Research Funding Mechanisms	The NCI uses grants, cooperative agreements, and contracts to help stimulate and fund cancer research.			CLICK HERE
16257	National Cancer Institute	Html	es	Prevención	La investigación del NCI de prevención va desde identificación de factores ambientales y de estilos de vida que influyen en el riesgo de cáncer hasta la biología de la formación del cáncer y la evaluación para diseminar intervenciones de prevención.	próxima generación 0.432035 Mejor reducción 0.436692 Investigación Nacional Colaborativa 0.455747 Investigación Oncológica 0.43883 Nuevos planteamientos 0.440499 investigación sustancias 0.43567 Estudio Vida Familiar 0.45233 Estados Unidos 0.908876 numerosos factores 0.443836 cabo estudios 0.446295 Cáncer apoya programas 0.610288	cánceres más 0.43473 numerosos estudios 0.443241 posibles terapias 0.437443 Pre-Cancer Atlas 0.437082 el  uso 0.430938 inmensa complejidad 0.437794 amplio rango 0.43275 prevención del cáncer del nci 0.509541 creación de  vacunas 0.467866 prueba formas 0.434098 Estados Unidos gastarán 0.466237	CLICK HERE
16648	National Cancer Institute	Html	en	Track 3: Oncology Product Research and Review for Postdoctoral Research Fellows	NCI and FDA collaborate to train physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety. Learn more about this cancer training program.	FDA medical product 0.724157 pharmacology/toxicology branch 0.567867 regulatory research 0.567201 manufacturing processes 0.657075 reviewer training 0.533228 FDA scientific review 0.647979 regulatory requirements 0.555708 regulatory meetings 0.534128 Medical Center Dr 0.604857 fellows 0.948854 product-related research 0.563223 molecular targeted therapy 0.645977 translational research 0.550405 manufacturing control 0.548537 research goals 0.538726 post-marketing surveillance 0.528754 quality control 0.651731 Regulatory Review Fellowships 0.633391 branch chief 0.620999 research activities 0.549015 pharmacology/toxicology reviews 0.559001 particular product division 0.677124 FDA Centers 0.6466 product standards 0.562937 quality assurance 0.652186	Review list 0.528745 training program 0.540221 various training activities 0.644892 relevant federal statutes 0.651561 formal training 0.557556 earliest start date 0.598748 critical ethical issues 0.628449 medical product development 0.721681 product research 0.592749 clinical trial design 0.65091 postdoctoral training 0.552346 product development 0.822368 regulatory presentations 0.533763 human research subjects 0.664846 guidance document development 0.635078 regulatory files 0.555901 principal investigators 0.629995 approval process 0.53653 NCI-FDA Research 0.537698 program time frame 0.62474 division director 0.626349 supplemental training 0.540819 regulatory experience 0.537743 cancer biology 0.538989	CLICK HERE